A Phase 1 trial that is testing Modex's vaccine against the Epstein-Barr virus, a strong risk factor for MS, has dosed its ...
Immunic Therapeutics says it's "on track" in its MS clinical trials of vidofludimus calcium, with CALLIPER top-line data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback